Navigation Links
New Test May Predict Prostate Cancer's Aggressiveness

Researchers say it can rule out men who don't need treatment

MONDAY, April 19 (HealthDay News) -- An updated version of the standard prostate cancer test can help improve predictions about which men might not require immediate treatment, researchers report.

The basic test measures blood levels of prostate-specific androgen (PSA), a protein produced by prostate gland cells. But the standard PSA test cannot distinguish between cancers that grow so slowly they can safely be left alone and aggressive life-threatening tumors that call for surgery or radiation therapy.

The new test measures blood levels of three different types of PSA. Combined with annual biopsies, or tissue samples, it was about 70 percent accurate in singling out the aggressive tumors in a small study, John Hopkins University researchers were to report Sunday at the American Association for Cancer Research annual meeting, in Washington, D.C.

"What we have shown is that using the Prostate Health Index and tissue DNA measurement is informative in separating out patients whose cancers are likely to progress vs. those that are not likely to progress," said study leader Robert W. Veltri, an associate professor of urology and oncology at Hopkins.

Prostate Health Index is the name given to the test by Beckman Coulter Inc., which plans to market it.

The study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.

Currently, identifying the dangerous tumors in that group is no better than "a coin-flip," Veltri said, and, as a result, many men and their doctors choose treatment that might be unnecessary and can cause impotence and other major problems.

Men in the trial had periodic blood tests that measured three different forms of PSA, including pro-PSA, a molecule in which two of the amino acids that make up the protein have been clipped off. It is the pro-PSA level that is most valuable as a predictor, Veltri said, but it is only one part of the study.

The new PSA test is given twice a year, along with a digital rectal exam to determine the size of the tumor, and a yearly biopsy. The regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said. "When you combine the DNA reading and the serum Prostate Health Index, it is accurate in about 7 out of 10 cases," he said.

But it was a small study, and "it will take another year or two to get enough cases to nail down the predictive index," Veltri said.

The Hopkins group is trying to identify other biomarkers that would improve the program's predictive value, he said. One hope is that the now-annual biopsies could be done every other year, Veltri said.

The study results have caused "excitement," he said. "Through active surveillance, we can identify a set of prostate cancer patients with low-grade tumors that may be able to have intervention deferred or delayed," Veltri said.

The Hopkins work was described as "outstanding" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.

The test is awaiting approval by the U.S. Food and Drug Administration and already is approved for use in Europe, Catalona said. In a study of 2,000 men in the Chicago area, "we found it to be more accurate than the tests now available, and it also seems to identify the more aggressive prostate cancers," he said.

Another report at the same meeting described use of a microchip to detect tumor cells in the blood of people with prostate cancer. The presence of circulating cells can indicate spread of the cancer to other parts of the body, but they are so rare that they are invisible to current technology.

The new circulating tumor cell (CTC) chip identified such cells in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer, providing important prognostic information, researchers at Massachusetts General Hospital reported.

More information

Learn about diagnosis and treatment of prostate cancer from the U.S. National Cancer Institute.

SOURCES: Robert W. Veltri, Ph.D., associate professor, urology and oncology, and director, Fisher Biorepository & Biomarker Laboratory, The Brady Urological Research Institute, Johns Hopkins Hospital, Baltimore; William J. Catalona, director, prostate cancer program, Northwestern Memorial Hospital Robert H. Lurie Comprehensive Cancer Center, and professor, urology, Northwestern University Feinberg School of Medicine, Chicago; April 18, 2010, American Association for Cancer Research annual meeting, Washington, D.C.

Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Routine breast cancer biopsy might predict lymph node cancer spread
2. £3M awarded for climate model to predict disease outbreak
3. M. D. Anderson zeroes in on better way to predict prognosis in pediatric leukemia patients
4. The Simple and Revolutionary Power to OUTSMART YOUR GENES Out April 6th -- Predictive Medicine Pioneer Dr. Brandon Colby Releases Book
5. Hip surgery success partially predicted by number of other existing conditions
6. Predicto Mobile Community Weighs in on Celebrity Weight Loss
7. Perception of poor sleep may predict postpartum mood disturbances in healthy new mothers
8. New clinical prediction index to help patients considering kidney transplant
9. Protein in Breast Tumors May Predict Chemo Response
10. In brain-injured children, early gesturing predicts language delays
11. Scans of brain networks may help predict injurys effects
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... hold the festivities in the friendly confines of their home. Whether it's making ... neighbors, try these Halloween recipes from Florida Dairy Farmers. , Recipe 1: ...
(Date:10/13/2015)... ... 2015 , ... Boulder native and lifelong athlete, Mark Gonglach, ... Tested by Olympic and professional athletes, he developed the combined massage and vibration ... sporting equipment and high-tech sales led him to transition from Rally Software to ...
(Date:10/13/2015)... ... October 13, 2015 , ... CURE Media ... today announced a new partnership with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) ... non-Hodgkin’s lymphoma, their families and physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ...
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... ... October 13, 2015 , ... In an age where the ... 36 percent lower per square foot than in 2009. The Williamsport Regional Medical Center ... and cooling has decreased by eight percent. , According to Facilities Management Administrative ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... ) has ... European markets for Meniscal Repair - 16 Countries ... ) has announced the addition of ... Repair - 16 Countries (2010-2021)" report to ... ( ) has announced the addition of ...
(Date:10/13/2015)... , Oct. 13, 2015   Vigilant Biosciences, Inc. ... that aid in the early detection and intervention of ... Vigilant,s founder and CEO, Matthew H.J. Kim , ... which recognizes an entrepreneur who has made extraordinary contributions ... life sciences industry in the leadership of a company ...
(Date:10/13/2015)... , Oct. 13, 2015  EndoChoice Holdings, Inc. ... third quarter 2015 financial results on Thursday, November 5, ... . --> . ... Thursday, November 5, 2015 at 9:00 a.m. ET to ... for domestic callers and (412) 317-5469 for international callers. ...
Breaking Medicine Technology: